From data silos to streamlined connectivity: how biopharma can prepare for ESMP

Published: 23-May-2025
Regulatory Pharma 5.0

Sponsors that centralise their product information will not only help to pre-empt drug shortages but also improve their capacity for collaboration with connected systems and data

You need to be a subscriber to read this article.
Click here to find out more.

Improving patient access to life-enhancing treatments is a central mission of companies ranging from the world’s largest biopharmaceutical manufacturers to early stage biotechs, reports Stephan Ohnmacht, Vice President, R&D Business Consulting at Veeva.

Each pursues its own path to get there. For some, the focus is on responsibly priced medicines. Others are amplifying patient voices during the medicine life cycle or using ESG bonds to reach underserved communities.1,2  

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Veeva Systems
See more

You may also like

Regulatory

Accumulus Synergy and Veeva Systems partner to boost life science connectivity

Read more
The companies aim to improve the exchange of regulatory data with national regulatory authorities through cloud connectivity

Trending Articles

  1. New RO system launched by NIPRO for dialysis clinics LiniXia system offers full heat disinfection, reduced downtime and up to 90% yield
  2. Aragen completes GMP biologics manufacturing site qualification The site is expected to be available for clinical and commercial-scale GMP production by late July
  3. Prioritising patient safety with PMS Effective as of 16 June 2025, the post-market surveillance (PMS) requirements mean that UK manufacturers must now have a robust process in place to monitor the safety and performance of medical devices after they are placed on the market
  4. EU GMP Annex 1 (August 2022): impact on cleaning and disinfection Cleaning and microbial contamination control are critical focus areas in the pharmaceutical and medical device industries. Robust cleaning and disinfection programmes are needed to meet the required cleanroom microbial grades, to prevent cross-contamination and the subsequent microbial spoilage of products
  5. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

You may also like

Regulatory

Accumulus Synergy and Veeva Systems partner to boost life science connectivity

The companies aim to improve the exchange of regulatory data with national regulatory authorities through cloud connectivity
Digital

The end of drug shortages begins with data transparency

Connecting quality, regulatory and manufacturing data is key to improving supply chain agility
Regulatory

Speed regulatory compliance with continuous publishing

Life science organisations are increasingly focusing on how they can improve the speed and efficiency of their operations
Media

Global survey reveals CROs leading industry wide shift to modernise clinical trial processes

Contract research organisations (CROs) are driving industry wide momentum to unify clinical systems and streamline trial processes, according to a new global industry survey from Veeva Systems
Regulatory

5 reasons why quality management needs a GxP-regulated cloud

The global shift from traditional IT offerings to cloud services continues
Regulatory

Vault CTMS offers new approach to streamline clinical trial management

Life science companies are moving to Veeva Vault CTMS for greater visibility and speed in clinical trials
Media

Open tech standards hold the key to better sponsor-CRO collaboration

Sponsors are under ever-increasing pressure to reduce the cost of drug development while accelerating time-to-market, expanding pipelines, improving drug quality and safety, and meeting ever-more-stringent expectations
Subscribe now